Asset profile
HEC88473
Peptide
Evidence outlook · lead readout
NCT05943886 · Healthy Subjects, Obesity, T2DM (Type 2 Diabetes Mellitus)
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05943886: The trial was randomized and fully blinded with a placebo comparator in each dose cohort, a solid design, but the primary outcome was safety and drug levels rather than a validated clinical or metabolic outcome, and results are not yet posted.
Scoped to the single-ascending-dose portion in healthy and obese subjects; the trial's type 2 diabetes arm is not covered by this publication.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.